Incyte Corp. Stock Underperforms Monday When Compared to Competitors

Dow Jones05:04

DJ Incyte Corp. Stock Underperforms Monday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Incyte Corp. $(INCY)$ slid 2.07% to $113.31 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.70% to 7,676.77 and the Dow Jones Industrial Average rising 0.28% to 52,361.58.

This was the stock's second consecutive day of losses.

Incyte Corp. closed 14.55% short of its 52-week high of $132.60, which the company reached on July 28th.

The stock underperformed when compared to some of its competitors Monday, as Alnylam Pharmaceuticals Inc. $(ALNY)$ rose 1.62% to $227.66, Bio-Techne Corp. (TECH) rose 0.19% to $72.69, and BioMarin Pharmaceutical Inc. $(BMRN)$ fell 0.36% to $55.75.

Trading volume (2.2 M) eclipsed its 50-day average volume of 1.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled October 26, 2026.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment